Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-interruption): A randomised trial

The Lancet

Volumn 384, Issue 9954, 2014, Pages 1577-1585

  Collet, Jean Philippe ^a   Silvain, Johanne ^a   Barthélémy, Olivier ^a   Rangé, Grégoire ^b   Cayla, Guillaume ^c   Van Belle, Eric ^d   Cuisset, Thomas ^e   Elhadad, Simon ^f   Schiele, François ^g   Lhoest, Nicolas ^h   Ohlmann, Patrick ⁱ   Carrié, Didier ^j   Rousseau, Hélène ^d,k   Aubry, Pierre ^l   Monségu, Jacques ^m   Sabouret, Pierre ^a   O'connor, Stephen A ^a   Abtan, Jérémie ^a   Kerneis, Mathieu ^a   Saint Etienne, Christophe ⁿ   Beygui, Farzin ^o   Vicaut, Eric ^k   Montalescot, Gilles ^a   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Les Hopitaux de Chartres   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e TIMONE HOSPITAL   (France)

^f Centre hospitalier de Lagny Marne la Vallee   (France)

^g UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^h GH du Centre Alsace   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j CHU RANGUEIL   (France)

^k HÔPITAL LARIBOISIÈRE   (France)

^l BICHAT HOSPITAL   (France)

^m INSTITUT MUTUALISTE MONTSOURIS   (France)

ⁿ SERVICE DE DERMATOLOGIE   (France)

^o CAEN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; THIENOPYRIDINE DERIVATIVE; ANTITHROMBOCYTIC AGENT; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY STENTING; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; FRANCE; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STENT THROMBOSIS; THROMBOCYTE FUNCTION; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASPIRIN; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PYRIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920126526     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60612-7     Document Type: Article

References (34)

1. Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
2. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
3. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA J Am Med Assoc 2007;297:159-68.
4. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
5. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
6. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501-55.
7. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-39.
8. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimuseluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011;58:1569-77.
9. Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012;33:606-13.
10. Sabate M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-90.
11. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54.
12. Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009;30:2714-21.
13. Kandzari DE, Barker CS, Leon MB, et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC CardiovascInterv 2011;4:1119-28.
14. Hahn J-Y, Song YB, Choi J-H, et al. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry. Circ J OffJ Jpn Circ Soc 2010;74:2314-21.
15. Naidu SS, Krucoff MW, Rutledge DR, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8, 061-patient XIENCE V United States study. JACC Cardiovasc Interv 2012;5:626-35.
16. Park S-J, Park D-W, Kim Y-H, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-82.
17. Valgimigli M, Campo G, Monti M, et al. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015-26.
18. Kim B-K, Hong M-K, Shin D-H, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavorzotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340-48.
19. Gwon H-C, Hahn J-Y, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505-13.
20. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA J Am Med Assoc 2013;310:2510-22.
21. Collet JP, Cayla G, Cuisset T, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoringguided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 2011;161:5-12.
22. Collet J-P, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-09.
23. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
24. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-17.
25. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-22.
26. Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
27. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
28. Byrne RA, Schulz S, Mehilli J, et al. Intracoronary stenting and antithrombotic regimen: safety and efficacy of six months dual antiplatelet therapy after drug-eluting stenting (ISAR-safe) investigators rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the intracoronary stenting and antithrombotic regimen: safety and efficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) study. Am Heart J 2009;157:620-24.
29. Mauri L, Kereiakes DJ, Normand S-LT, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drugeluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-41.
30. Aradi D, Storey RF, Komocsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2013;35:209-15.
31. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261-73.
32. Montalescot G, Vicaut E, Collet J-P. Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med 2013;368:871-72.
33. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014;167:437-44.
34. Mauri L, Kereiakes DJ, Normand S-LT, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drugeluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-41.